|
|
Volumn 28, Issue 28, 2010, Pages
|
|
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CALCITONIN;
CARCINOEMBRYONIC ANTIGEN;
BENZENESULFONIC ACID DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PYRIDINE DERIVATIVE;
SORAFENIB;
TUMOR MARKER;
BONE METASTASIS;
CANCER SIZE;
DRUG TARGETING;
HUMAN;
LETTER;
LIVER METASTASIS;
LUNG METASTASIS;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
PRIORITY JOURNAL;
THYROID GLAND;
THYROID MEDULLARY CARCINOMA;
TREATMENT RESPONSE;
DISEASE FREE SURVIVAL;
ENZYMOLOGY;
GENETICS;
LYMPHADENECTOMY;
MEDULLARY CARCINOMA;
METABOLISM;
METASTASIS;
MORTALITY;
NOTE;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL;
THYROID TUMOR;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
BENZENESULFONATES;
CALCITONIN;
CARCINOEMBRYONIC ANTIGEN;
CARCINOMA, MEDULLARY;
CLINICAL TRIALS, PHASE II AS TOPIC;
DISEASE-FREE SURVIVAL;
HUMANS;
LYMPH NODE EXCISION;
LYMPHATIC METASTASIS;
PROTEIN KINASE INHIBITORS;
PYRIDINES;
THYROID NEOPLASMS;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 78049430435
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2010.29.9909 Document Type: Letter |
|
Times cited : (4)
|
|
References (4)
|
